Modality
ERT
MOA
TYK2i
Target
PI3Kα
Pathway
Notch
HCCNASHMeso
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
~Dec 2023
→ ~Mar 2025
Phase 3
Jun 2025
→ Jun 2027
Phase 3Current
NCT06274601
2,947 pts·Meso
2025-06→2027-06·Terminated
NCT06626858
890 pts·NASH
2025-09→TBD·Not yet recruiting
3,837 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-051.2y awayPh3 Readout· Meso
Trial Timeline
Q3Q42026Q2Q3Q42027Q2
P3
Termina…
P3
Not yet…
Catalysts
Ph3 Readout
2027-06-05 · 1.2y away
Meso
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06274601 | Phase 3 | Meso | Terminated | 2947 | DOR |
| NCT06626858 | Phase 3 | NASH | Not yet recr... | 890 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |